Liliane Nkengurutse

Dr. Liliane Nkengurutse

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2025 in Viruses
Verified
Journal Article
Open access
PDF file
LNLiliane Nkengurutse
Liliane Nkengurutse
JOJohn Otokoye OTSHUDIEMA
John Otokoye OTSHUDIEMA
GKGodefroid Kamwenubusa
Godefroid Kamwenubusa
IDIssa Diallo
Issa Diallo
ONOdette Nsavyimana
Odette Nsavyimana
SHStanislas Harakandi
Stanislas Harakandi
(1) Objectives: Studies on mpox patterns, severity predictors, and public health impacts in Burundi remain limited. Therefore, we aimed to identify the clinical predictors and determinants of mpox complications among hospitalized patients in Bujumbura, Burundi, during an active outbreak. (2) Methods: We conducted a prospective cohort study of laboratory-confirmed mpox cases across three treatment centers (July–October 2024). Clinical characteristics and outcomes were assessed through a systematic review of medical and laboratory records supplemented by structured interviews with patients or caregivers. Risk factors for disease complications were evaluated using multivariate Firth penalized logistic regression. (3) Results: Complications developed in 3.1% of 850 patients (54.4% male; median age, 20.3 years). Conjunctivitis (odds ratio [OR]: 27.30; 95% confidence interval [CI], 7.67–122.23) and sore throat (OR: 12.63; 95% CI, 5.78–30.21) were significant predictors of severe disease progression. Conversely, generalized rash (OR, 0.10; 95% CI, 0.04–0.24) and lymphadenopathy (OR, 0.24; 95% CI, 0.08–0.62) were associated with a mild disease course. Sexual transmission was the predominant route of infection (58.6%). (4) Conclusions: Noncutaneous manifestations, particularly conjunctivitis and sore throat, are early indicators of mpox severity. These findings inform clinical risk stratification in resource-limited settings and highlight the need for further investigation of pathophysiological mechanisms.

27 February 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
LNLiliane Nkengurutse
Liliane Nkengurutse
JOJohn Otokoye OTSHUDIEMA
John Otokoye OTSHUDIEMA
GKGodefroid Kamwenubusa
Godefroid Kamwenubusa
IDIssa Diallo
Issa Diallo
ONOdette Nsavyimana
Odette Nsavyimana
SHStanislas Harakandi
Stanislas Harakandi
(1) Objectives: Studies on mpox patterns, severity predictors, and public health impacts in Burundi remain limited. Therefore, we aimed to identify the clinical predictors and determinants of mpox complications among hospitalized patients in Bujumbura, Burundi, during an active outbreak. (2)Methods: We conducted a prospective cohort study of laboratory-confirmed mpox cases across three treatment centers (July-October 2024). Clinical characteristics and outcomes were assessed through a systematic review of medical and laboratory records supplemented by structured interviews with patients or caregivers. Risk factors for disease complications were evaluated using multivariate Firth penalized logistic regression. (3)Results: Complications developed in 3.1% of 850 patients (54.4% male; median age, 20.3 years). Conjunctivitis (odds ratio [OR]: 27.30; 95% confidence interval [CI], 7.67–122.23) and sore throat (OR: 12.63; 95% CI, 5.78–30.21) were significant predictors of severe disease progression. Conversely, generalized rash (OR, 0.10; 95% CI, 0.04–0.24) and lymphadenopathy (OR, 0.24; 95% CI, 0.08–0.62) were associated with a mild disease course. Sexual transmission was the predominant route of infection. (4)Conclusions: Noncutaneous manifestations, particularly conjunctivitis and sore throat, are early indicators of mpox severity. These findings inform clinical risk stratification in resource-limited settings and highlight the need for further investigation of pathophysiological mechanisms.

27 February 2026 in medRxiv
Verified
Preprint
Open access
PDF file
RMRuth McCabe
Ruth McCabe
EKEdward Knock
Edward Knock
AHAlba Halliday
Alba Halliday
VCVictoria M Cox
Victoria M Cox
DMDaniela Olivera Mesa
Daniela Olivera Mesa
LWLilith K Whittles
Lilith K Whittles
In 2024, mpox cases surged in the Democratic Republic of the Congo (DRC) with cross-border spread to Burundi. We developed a transmission-dynamic model calibrated against surveillance data to understand drivers in enzootic (Clade Ia) and non-enzootic (Clade Ib) areas, and the potential impact of vaccination. In non-enzootic areas we estimated that 58-84% of transmission occurred within sexual networks. MVA-BN vaccination of sex workers could have averted 91% (95% CrI 81%–98%) of infections in Sud Kivu (DRC) but only 35% (95% CrI 26%–47%) in Bujumbura (Burundi), due to later outbreak detection. In historically enzootic Equateur (DRC), ongoing zoonotic spillover best explained sustained incidence. There, pledged Lc18m8 vaccines could have averted 42% (95% CrI 40%–46%) of infections; prioritising children improved impact. Across all settings, doubling vaccine coverage by using a single dose of MVA-BN outperformed two-dose strategies. Timely detection and tailored vaccination strategies are critical to reducing mpox burden.

20 July 2026 in Journal of Infection and Public Health
Verified
Journal Article
Open access
JOJohn Otokoye OTSHUDIEMA
John Otokoye OTSHUDIEMA
LNLiliane Nkengurutse
Liliane Nkengurutse
GKGodefroid Kamwenubusa
Godefroid Kamwenubusa
IDIssa Diallo
Issa Diallo
ASAimable SIBOMANA
Aimable SIBOMANA
JNJoseph Nyandwi
Joseph Nyandwi
In Africa, the transmission of Monkeypox (mpox), especially in countries that were initially unaffected, including Burundi, is still inefficiently reported. This study has analyzed various demographics and cases, alongside the transmission pathways and risk factors to apprise effective, setting-specific control strategies for mitigation of mpox outbreaks while also guiding prospective responses to similar outbreaks in resource-restricted contexts. To effectively characterize the transmission patterns of clade Ib monkeypox virus, the study evaluated the laboratory-confirmed mpox cases in Bujumbura, Burundi, alongside their contacts, as from 25th July 2024-26 th October 2024. Collection of data was mainly done via patient interviews, national surveillance data, and electronic health records. A total of 850 laboratory-confirmed mpox cases alongside 7773 acknowledged contacts were included in the study. The average age of the patients was 20.3 (interquartile range: 22.0; range: 3 months-71 years), while a larger proportion of the patients (71.9%) comprised children aged < 5 years and younger adults aged between 16 years and 29 years. Sexual contact (58.6%) and household exposure (38.6%) were found to be the primary transmission routes. The basic reproduction number was 1.21 (95% CI (confidence interval): 1.11-1.31), with 14.0% secondary attack rates (95% CI: 12.1-15.9) among sexual contacts, as well as 13.0% (95% CI: 11.2-14.8) among household contacts. The average incubation period was found to be 9.5 days (95% CI: 7.5-11.4), while the serial interval was 15.5 days (95% CI: 12.4-18.7). To effectively control and manage mpox outbreak in resource-restricted contexts, the study findings have stressed on the requirement for targeted interventions to tackle sexual contact networks alongside household transmissions.